Vironexx develops first-in-class monoclonal antibodies with the ability to prevent and cure hepatitis C infection, which progressively causes liver damage. They will target patients for whom there is currently no treatment option: transplant patients and multidrug-resistant patients with available therapies. Vironexx will deliver a preclinical